Research and Markets has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016" report to their offering.
'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016'; Alpha- Antitrypsin Deficiency pipeline therapeutics constitutes close to 21 molecules. Out of which approximately 21 molecules are developed by Companies.
Furthermore, the publisher says; Alpha- Antitrypsin Deficiency Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.
The report 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies.
It also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 2, 1, 10 and 3 respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/c8ptzk/alpha
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005836/en/Business Wire
Last updated on: 12/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.